# Contents

**Program Faculty**..............................................................................................................................................................i

**Sponsorship and CME Credit**...........................................................................................................................................ii

**CME Activity Assessment and Evaluation**...........................................................................................................................iv

---

**Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference**


---

Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer
Roman Perez-Soler..........................................................................................................................................

---

**HKI-272 in Non–Small Cell Lung Cancer**
Kwok-Kin Wong..............................................................................................................................................

---

Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer:
Current Status of Matuzumab and Panitumumab
Mark A. Socinski ...............................................................................................................................................

---

Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?
Daniel Morgensztern and Ramaswamy Govindan ..........................................................................................

---

Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Philip D. Bonomi, Lela Buckingham, and John Coon.....................................................................................

---

Bevacizumab in Non–Small Cell Lung Cancer
Alan Sandler.....................................................................................................................................................

---

Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
Emer O. Hanrahan and John V. Heymach.................................................................................................................

---

Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
Gregory J. Riely and Vincent A. Miller....................................................................................................................

---

Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer
Bruce E. Johnson, David Jackman, and Pasi A. Jänne..............................................................................................

---

Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer:
Rationale and Investigations
Julie E. Bauman, Keith D. Eaton, and Renato G. Martins...........................................................................................

---

The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
Jeffrey A. Engelman...........................................................................................................................................

---

Enzastaurin, a Protein Kinase Cβ-Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer
Roy S. Herbst, Yun Oh, Asavari Wagle, and Michael Lahn..........................................................................................

---

Incorporating Bortezomib into the Treatment of Lung Cancer
Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara......................................................

---

L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
Randeep Sangha and Charles Butts ..........................................................................................................................
Clinical Cancer Research

13 (15)


| Updated version | Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/13/15 |

| E-mail alerts | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions | To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org. |